Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986178 alone or with nivolumab and/or ipilimumab in advanced solid tumors
NL-OMON47099Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of BMS-986178 in Nonhematologic neoplasms, melanoma, non-small cell lung cancer (NSCLC) and 16 more (7 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and tolerability, Dose-limiting toxicities and 1 more. Started Jun 2016; status: completed.
02
Drugs
BMS-986178
03
Conditions
Nonhematologic neoplasmsmelanomanon-small cell lung cancer (NSCLC)head and neck cancer (HNC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON47099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47099.